logo-loader
viewGenprex, Inc.

Genprex strengthens its team with new VP of clinical operations

Genprex Inc (NASDAQ:GNPX) COO Julien Pham tells Proactive Investors the clinical-stage gene therapy company has appointed Jan Stevens as its vice president of clinical operations.

According to Pham, Stevens will support clinical development programs for the company’s immunogene therapy Oncoprex, which is being evaluated in clinical studies at the MD Anderson Cancer center for the treatment of non-small cell lung cancer.

Pham adds Stevens has nearly 20 years of clinical operations experience in the biopharma industry.

Quick facts: Genprex, Inc.

Price: 0.4 USD

NASDAQ:GNPX
Market: NASDAQ
Market Cap: $6.34 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Genprex's active drug ingredient validated by independent...

Genprex (NASDAQ:GNPX) CEO Rodney Varner tells Proactive that the active ingredient in the biotech firm's immunogene therapy Oncoprex has been shown to prevent tumor growth in triple-negative breast cancer patients by an independent researcher. Varner notes the study was published in the...

on 09/20/2019

2 min read